Pandemic News and Research RSS Feed - Pandemic News and Research

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.
BiondVax Pharmaceuticals intends to close trading on NASDAQ market on July 10, 2015

BiondVax Pharmaceuticals intends to close trading on NASDAQ market on July 10, 2015

​BiondVax Pharmaceuticals Ltd. today announced that it will be closing trading on the NASDAQ market on Friday, July 10, 2015, in celebration of its recent initial public offering in the United States and the launch of its international investor relations program. [More]
Researchers receive $1.35 million grant to study how influenza virus passes from birds to humans

Researchers receive $1.35 million grant to study how influenza virus passes from birds to humans

An international research team led by Lukas Tamm of the University of Virginia School of Medicine will receive $1.35 million from the Human Frontier Science Program Organization to better understand how the influenza virus passes from birds to humans. [More]
BiondVax Pharmaceuticals declares closing of over-allotment option granted to underwriters

BiondVax Pharmaceuticals declares closing of over-allotment option granted to underwriters

​BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced the closing of an additional and partial exercise of the over-allotment option granted to the underwriters. [More]
Generic heart disease drugs show promise in patients affected by Ebola virus

Generic heart disease drugs show promise in patients affected by Ebola virus

Generic medications used frequently in the management of heart disease patients also have the potential to bolster the immune systems of patients with Ebola virus and some other life-threatening illnesses, researchers report this week in mBio, the online open-access journal of the American Society for Microbiology. [More]
Public health experts outline strategies for managing MERS-CoV outbreak

Public health experts outline strategies for managing MERS-CoV outbreak

The ongoing outbreak in the Republic of Korea (South Korea) is an important reminder that the Middle East respiratory virus (MERS-CoV) requires constant vigilance and could spread to other countries including the United States. However, MERS can be brought under control with effective public health strategies, say two Georgetown University public health experts. [More]
FDA accepts BiondVax's IND for Multimeric-001 vaccine

FDA accepts BiondVax's IND for Multimeric-001 vaccine

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced that its Investigational New Drug Application (IND) for its Multimeric-001 vaccine (M-001), has been accepted by the US Food and Drug Administration, and the Company was notified by its regulatory advisors that the 'study may proceed'. [More]
St. Michael's Hospital researchers find novel method to combat flu virus

St. Michael's Hospital researchers find novel method to combat flu virus

The flu kills hundreds of thousands of people around the world every year, yet there is essentially only one class of drugs to fight the ever-changing virus. Cases of flu resistant to this class of drugs have already been reported and researchers worry a completely new strain of flu could evolve, leading to a pandemic like the one in 1918 that killed approximately 50 million people. [More]
Designing infectious disease forecasting models to predict dengue epidemics

Designing infectious disease forecasting models to predict dengue epidemics

Dengue viruses are on the move. Spread among humans by mosquitoes, and across geographic boundaries through travel, the virus affects up to an estimated 390 million people every year around the world. In the U.S., recent outbreaks have occurred in Florida, Texas, Hawaii, and Puerto Rico. Scientists know one of the best ways to reduce the impact of the disease is to prepare healthcare providers by forecasting epidemics before they happen. [More]
The Lancet publishes new Seminar on MERS

The Lancet publishes new Seminar on MERS

Middle East respiratory syndrome (MERS) has recently returned to the headlines as new cases have been exported to Korea and China. Experts are concerned that MERS cases continued to be detected in Saudi Arabia throughout the past year, and there appears to be little reduction in the number of cases since its first discovery three years ago. As the month of Ramadan approaches, with 1 million pilgrims expected to arrive in Saudi Arabia in June and July 2015, MERS remains a threat to global health security. [More]
New finding may lead to development of immunity-based therapies for tuberculosis

New finding may lead to development of immunity-based therapies for tuberculosis

A study by researchers at UT Southwestern Medical Center has identified how an enzyme involved in protecting the body from pathogens senses Mycobacterium tuberculosis (TB), a bacterial pathogen that infects millions of people worldwide and causes about 1.5 million deaths annually. [More]
Two new groups of viruses discovered within Bunyavirus family in Ivory Coast tropical forest

Two new groups of viruses discovered within Bunyavirus family in Ivory Coast tropical forest

Researchers at the University of Bonn and the German Center for Infection Research (DZIF) have discovered two new groups of viruses within the Bunyavirus family in the tropical forest of Ivory Coast. Previously only five groups responsible for serious illnesses in humans and animals were known. [More]
BiondVax provides update on financial results for first quarter 2015

BiondVax provides update on financial results for first quarter 2015

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced its financial results for the first quarter of 2015 and provided a business update. [More]
TB Alliance announces start of clinical trial to treat XDR-TB

TB Alliance announces start of clinical trial to treat XDR-TB

TB Alliance and its partners announced the start of a clinical trial of a new regimen to treat extensively drug-resistant tuberculosis (XDR-TB). It is the first study to test an all-oral drug regimen, comprised of drugs with minimal pre-existing resistance, that has the potential to shorten, simplify, and improve treatment for XDR-TB. [More]
Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen. [More]
BD reports revenues of $2.051 billion for second fiscal quarter 2015

BD reports revenues of $2.051 billion for second fiscal quarter 2015

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for the second fiscal quarter ended March 31, 2015, representing a decrease of 1.0 percent from the prior-year period, or an increase of 4.9 percent on a foreign currency-neutral basis. [More]
NanoPass signs license agreement for supply of MicronJet600 device to Circassia

NanoPass signs license agreement for supply of MicronJet600 device to Circassia

NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for the supply of MicronJet600, its microneedle delivery device, to Circassia Pharmaceuticals plc. (Oxford, UK), a specialty biopharmaceutical company focused on the allergy market. [More]
Texas Biomed scientists awarded NIH grant to develop potential HPV-based HIV vaccine

Texas Biomed scientists awarded NIH grant to develop potential HPV-based HIV vaccine

Scientists at Texas Biomedical Research Institute have begun work on a nearly $3.4 million study funded by the National Institutes of Health over the next four years to create an attenuated, or weakened, virus that is a hybrid of the papilloma virus and the human immunodeficiency virus, with the potential to jumpstart a body's immune response to develop antibodies against both viruses. [More]
SLU selected to work on universal flu vaccine project

SLU selected to work on universal flu vaccine project

Supported by a federal contract, Saint Louis University will study a concept for a universal flu vaccine that is designed to protect people from influenza pandemics that could turn deadly as well as seasonal flu caused by the influenza A virus. [More]
Lab-on-paper technique could help detect low quality antimalarial drugs

Lab-on-paper technique could help detect low quality antimalarial drugs

Access to high-quality medicine is a basic human right, but over four billion people live in countries where many medications are substandard or fake. Marya Lieberman of the Department of Chemistry and Biochemistry at the University of Notre Dame and Abigail Weaver a postdoctoral associate in the University's Department of Civil Engineering and Environmental and Earth Sciences took up the challenge of how people in developing countries could detect low quality antimalarial drugs without expensive equipment and without handling dangerous chemicals. [More]
UC San Diego study examines counterfeit drug penetration in global medicine supply chains

UC San Diego study examines counterfeit drug penetration in global medicine supply chains

When you take a medication for, say, high cholesterol, do you know that pill is really what the label says it is? Depending upon the type of medicine and where you live, the threat of falsified medications (also referred to as counterfeit, fraudulent, and substandard) can be quite real, yet the full scope and prevalence of the problem is poorly understood, say researchers at University of California, San Diego School of Medicine in a new report published April 20 in the American Journal of Tropical Medicine and Hygiene. [More]
Advertisement
Advertisement